United Therapeutics Corporation Company Profile (NASDAQ:UTHR)

About United Therapeutics Corporation (NASDAQ:UTHR)

United Therapeutics Corporation logoUnited Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca). The Company markets and sells an oncology product in the United States, Unituxin (dinutuximab) Injection (Unituxin), which is approved for treatment of neuroblastoma. The Company is also engaged in early-stage research and development of a number of organ transplantation-related technologies.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology & Medical Research
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:UTHR
  • CUSIP: 91307C10
  • Web: www.unither.com
Capitalization:
  • Market Cap: $4.98 billion
  • Outstanding Shares: 43,442,000
Average Prices:
  • 50 Day Moving Avg: $128.37
  • 200 Day Moving Avg: $129.08
  • 52 Week Range: $110.90 - $169.89
P/E:
  • Trailing P/E Ratio: 13.74
  • Foreward P/E Ratio: 10.75
  • P/E Growth: -0.41
Sales & Book Value:
  • Annual Revenue: $1.63 billion
  • Price / Sales: 3.05
  • Book Value: $40.89 per share
  • Price / Book: 2.80
Profitability:
  • EBIDTA: $1.01 billion
  • Net Margins: 24.18%
  • Return on Equity: 20.96%
  • Return on Assets: 16.03%
Debt:
  • Current Ratio: 1.86%
  • Quick Ratio: 1.73%
Misc:
  • Average Volume: 594,052 shs.
  • Beta: 1.52
  • Short Ratio: 15.02
 

Frequently Asked Questions for United Therapeutics Corporation (NASDAQ:UTHR)

What is United Therapeutics Corporation's stock symbol?

United Therapeutics Corporation trades on the NASDAQ under the ticker symbol "UTHR."

How will United Therapeutics Corporation's stock buyback program work?

United Therapeutics Corporation announced that its Board of Directors has authorized a share repurchase plan on Sunday, June 4th 2017, which authorizes the company to buyback $250,000,000.00 in shares, according to EventVestor. This buyback authorization authorizes the company to reacquire up to 4.6% of its stock through open market purchases. Stock buyback plans are generally a sign that the company's board of directors believes its stock is undervalued.

How were United Therapeutics Corporation's earnings last quarter?

United Therapeutics Corporation (NASDAQ:UTHR) released its earnings results on Thursday, July, 27th. The company reported ($1.25) earnings per share for the quarter, missing the Zacks' consensus estimate of $3.61 by $4.86. The firm had revenue of $444.60 million for the quarter, compared to the consensus estimate of $391.53 million. United Therapeutics Corporation had a net margin of 24.18% and a return on equity of 20.96%. The company's revenue for the quarter was up 7.8% compared to the same quarter last year. During the same quarter last year, the company posted $4.42 EPS. View United Therapeutics Corporation's Earnings History.

When will United Therapeutics Corporation make its next earnings announcement?

United Therapeutics Corporation is scheduled to release their next quarterly earnings announcement on Thursday, October, 26th 2017. View Earnings Estimates for United Therapeutics Corporation.

Where is United Therapeutics Corporation's stock going? Where will United Therapeutics Corporation's stock price be in 2017?

11 brokerages have issued 1 year price targets for United Therapeutics Corporation's shares. Their predictions range from $95.00 to $213.00. On average, they expect United Therapeutics Corporation's stock price to reach $134.70 in the next year. View Analyst Ratings for United Therapeutics Corporation.

What are analysts saying about United Therapeutics Corporation stock?

Here are some recent quotes from research analysts about United Therapeutics Corporation stock:

  • 1. According to Zacks Investment Research, "United Therapeutics holds a strong position in the pulmonary arterial hypertension (PAH) market with four approved products targeting this indication. The company is working on new delivery mechanisms for Remodulin and expanded indications for its other marketed products like Orenitram and Tyvaso to drive long-term growth. However, competition in the PAH market is on the rise. Lately, the growth of its PAH drugs Orenitram, Tyvaso and Remodulin have slowed due to competition from Uptravi and Adcirca + Letairis combination therapy. Recently, United Therapeutics announced that regulatory issues will delay the U.S. launch of RemoSynch. Adcirca is also expected to lose patent exclusivity in Nov 2017. United Therapeutics’ shares underperformed the drugs industry this year so far. Estimates have remained stable ahead of the Q2 earnings release. The company has a record of positive earnings surprises in the recent quarters." (7/13/2017)
  • 2. Cowen and Company analysts commented, "1Q Revenues were weak across the prostacyclin PAH franchise." (4/26/2017)
  • 3. Credit Suisse Group analysts commented, "The recent acquisition of UTHR's competitor has driven a large M&A premium in UTHR shares, and we see downside due to potential near-term and generic risk starting late 2017-2018. United Therapeutics' product franchise consists of pulmonary arterial hypertension (PAH) therapies. PAH is essentially high blood pressure in the lungs. We think an acquisition for United Therapeutics is unlikely in the near term since the company has mentioned doing deals to acquire. We see catalysts in the coming month that could lead to downside in shares, especially with shares trading above (~20%), the level at which we see the fundamental value of the company. In the long term, we remain more cautious on what the current valuation would suggest around risk to UTHR's PAH franchise from generics launching as early as 2018. We think that the stock trades at a higher non-GAAP P/E multiple than what consensus actually shows; we estimate 2018 and 2019 P/E multiples of 15x and 20x vs. consensus of 10x and 11x, respectively." (3/16/2017)
  • 4. Jefferies Group LLC analysts commented, "Our physician poll indicates continuing competitor Uptravi impact on UTHR's treprostinil franchise & meaningful headwinds from generic Remodulin - potentially ~35% of current sales at risk. Yet, current consensus est's do not reflect such downside risks, particularly a potential real threat from generic Remodulin in 2018. Downgrading UTHR to Underperform from Hold, but keeping $116 PT." (3/6/2017)
  • 5. Wedbush analysts commented, "With consistent YoY growth in revenues, free cash flow and a deep pipeline of diverse assets in late-stage development, we continue to believe UTHR continues to be an attractive long-term investment. ' Q4 and 2016 top and bottom line missed on seasonal choppiness and transient warehousing of Remodulin and Tyvaso patients. Reported Q4/FY:16 revenues of $409MM/$1599MM came in below consensus estimates of $416MM/$1605MM. GAAP EPS of $2.43/$15.25 also missed consensus estimates of $3.68/$16.46. While Remodulin and Adcirca beat, Tyvaso and Orenitram missed. Management indicated their view that patient warehousing with oral PAH medications is transient and anticipates sales acceleration for Tyvaso and Remodulin later in 2017 as the effect of oral PAH medications begins to wane and PAH patients need a new medication. UTHR ended 2016 with ~$1.053BN in cash & cash eq. Management implied that instead of pursing another share buyback, they may announce business development activities." (2/27/2017)

Who are some of United Therapeutics Corporation's key competitors?

Who are United Therapeutics Corporation's key executives?

United Therapeutics Corporation's management team includes the folowing people:

  • Martine A. Rothblatt Ph.D. J.D., Chairman of the Board, Chief Executive Officer
  • Michael Benkowitz, President, Chief Operating Officer
  • Christopher Patusky J.D., Lead Independent Vice Chairman of the Board
  • James C. Edgemond, Chief Financial Officer, Treasurer
  • Paul A. Mahon J.D., Executive Vice President, General Counsel, Corporate Secretary
  • Raymond A. Dwek, Non-Independent Director
  • Christopher Causey, Independent Director
  • Richard A. Giltner, Independent Director
  • Katherine J. Klein Ph.D., Independent Director
  • Raymond C. Kurzweil J.D., Independent Director

Who owns United Therapeutics Corporation stock?

United Therapeutics Corporation's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (11.27%), FMR LLC (9.79%), Vanguard Group Inc. (8.77%), State Street Corp (4.64%), Palo Alto Investors LLC (4.30%) and Acadian Asset Management LLC (2.53%). Company insiders that own United Therapeutics Corporation stock include Christopher Causey, Christopher Patusky, Martine A Rothblatt, Paul A Mahon, Raymond Dwek, Richard Giltner and Tommy G Thompson. View Institutional Ownership Trends for United Therapeutics Corporation.

Who sold United Therapeutics Corporation stock? Who is selling United Therapeutics Corporation stock?

United Therapeutics Corporation's stock was sold by a variety of institutional investors in the last quarter, including AJO LP, LSV Asset Management, Los Angeles Capital Management & Equity Research Inc., WINTON GROUP Ltd, TIAA CREF Investment Management LLC, Old Mutual Global Investors UK Ltd., Westpac Banking Corp and Cornerstone Capital Management Holdings LLC.. Company insiders that have sold United Therapeutics Corporation stock in the last year include Christopher Causey, Christopher Patusky, Martine A Rothblatt, Raymond Dwek, Richard Giltner and Tommy G Thompson. View Insider Buying and Selling for United Therapeutics Corporation.

Who bought United Therapeutics Corporation stock? Who is buying United Therapeutics Corporation stock?

United Therapeutics Corporation's stock was bought by a variety of institutional investors in the last quarter, including Wells Fargo & Company MN, JPMorgan Chase & Co., Renaissance Technologies LLC, Schroder Investment Management Group, Dimensional Fund Advisors LP, Prudential Financial Inc., BlackRock Inc. and FMR LLC. View Insider Buying and Selling for United Therapeutics Corporation.

How do I buy United Therapeutics Corporation stock?

Shares of United Therapeutics Corporation can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is United Therapeutics Corporation's stock price today?

One share of United Therapeutics Corporation stock can currently be purchased for approximately $114.60.


MarketBeat Community Rating for United Therapeutics Corporation (NASDAQ UTHR)
Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  299 (Vote Outperform)
Underperform Votes:  385 (Vote Underperform)
Total Votes:  684
MarketBeat's community ratings are surveys of what our community members think about United Therapeutics Corporation and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for United Therapeutics Corporation (NASDAQ:UTHR) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 3 Sell Ratings, 6 Hold Ratings, 2 Buy Ratings
Consensus Rating:Hold (Score: 1.91)
Consensus Price Target: $134.70 (17.54% upside)

Analysts' Ratings History for United Therapeutics Corporation (NASDAQ:UTHR)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
9/8/2017Oppenheimer Holdings, Inc.Reiterated RatingBuyLowView Rating Details
7/14/2017Jefferies Group LLCReiterated RatingSell$105.00LowView Rating Details
4/27/2017WedbushReiterated RatingOutperform -> Outperform$229.00 -> $213.00LowView Rating Details
4/26/2017Cowen and CompanyReiterated RatingHold$121.00LowView Rating Details
4/17/2017HC WainwrightReiterated RatingHold$95.00LowView Rating Details
4/11/2017J P Morgan Chase & CoSet Price TargetHold$125.00LowView Rating Details
4/3/2017Credit Suisse GroupReiterated RatingUnderperform$120.00HighView Rating Details
2/23/2017Ladenburg Thalmann Financial ServicesDowngradeBuy -> Neutral$145.00N/AView Rating Details
2/23/2017Leerink SwannBoost Price TargetMarket Perform$127.00 -> $148.00N/AView Rating Details
1/19/2017Standpoint ResearchDowngradeBuy -> HoldN/AView Rating Details
11/29/2016Barclays PLCDowngradeEqual Weight -> Underweight$115.00 -> $100.00N/AView Rating Details
8/23/2016ArgusReiterated RatingHoldN/AView Rating Details
4/11/2016Royal Bank Of CanadaReiterated RatingSector Perform$150.00 -> $122.00N/AView Rating Details
(Data available from 9/23/2015 forward)

Earnings

Earnings History for United Therapeutics Corporation (NASDAQ:UTHR)
Earnings by Quarter for United Therapeutics Corporation (NASDAQ:UTHR)
Earnings History by Quarter for United Therapeutics Corporation (NASDAQ UTHR)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
10/25/2017$3.69N/AView Earnings Details
7/27/2017Q2 2017$3.61($1.25)$391.53 million$444.60 millionViewN/AView Earnings Details
4/26/2017Q1 2017$3.13$3.89$399.59 million$370.50 millionViewN/AView Earnings Details
2/22/2017Q416$3.61$4.12$415.51 million$409.00 millionViewListenView Earnings Details
10/27/2016Q316$3.38$4.36$400.58 million$408.20 millionViewListenView Earnings Details
7/28/2016Q216$3.22$4.55$395.15 million$412.60 millionViewListenView Earnings Details
4/28/2016Q116$3.21$3.02$395.02 million$369.00 millionViewListenView Earnings Details
2/25/2016Q415$2.70$3.68$388.29 million$404.90 millionViewListenView Earnings Details
10/27/2015Q315$2.35$3.55$363.51 million$386.20 millionViewListenView Earnings Details
7/28/2015Q215$2.31$2.55$360.41 million$347.20 millionViewListenView Earnings Details
4/28/2015Q115$2.14$2.55$353.50 million$327.60 millionViewN/AView Earnings Details
2/24/2015Q414$2.03$3.21$336.22 million$346.40 millionViewN/AView Earnings Details
10/28/2014Q314$1.97$3.91$335.10 million$330.00 millionViewN/AView Earnings Details
7/29/2014Q214$1.75$2.57$308.04 million$322.80 millionViewN/AView Earnings Details
4/29/2014Q114$1.65$1.77$300.14 million$289.40 millionViewN/AView Earnings Details
2/25/2014Q413$1.51$2.88$295.43 million$289.02 millionViewN/AView Earnings Details
10/29/2013Q313$1.59$2.98$279.02 million$302.20 millionViewN/AView Earnings Details
7/25/2013Q2 2013$1.47$1.52$250.17 million$280.60 millionViewN/AView Earnings Details
4/25/2013Q1 2013$1.47$1.19$241.14 million$245.14 millionViewN/AView Earnings Details
2/26/2013Q4 2012$1.25$1.65$233.41 million$243.82 millionViewN/AView Earnings Details
11/1/2012Q312$1.26$2.82$227.63 million$242.50 millionViewN/AView Earnings Details
7/26/2012$1.23$1.34ViewN/AView Earnings Details
4/26/2012$1.00$1.32ViewN/AView Earnings Details
2/14/2012$0.85$0.77ViewN/AView Earnings Details
10/27/2011$0.88$1.32ViewN/AView Earnings Details
7/28/2011$0.49$1.27ViewN/AView Earnings Details
4/28/2011$0.64$1.29ViewN/AView Earnings Details
2/15/2011$0.62$0.15ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for United Therapeutics Corporation (NASDAQ:UTHR)
2017 EPS Consensus Estimate: $14.45
2018 EPS Consensus Estimate: $13.35
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20174$3.08$3.89$3.37
Q2 20174$3.43$4.47$3.81
Q3 20174$3.48$4.06$3.82
Q4 20174$3.08$3.81$3.45
Q1 20181$3.61$3.61$3.61
Q2 20181$3.15$3.15$3.15
Q3 20181$3.31$3.31$3.31
Q4 20181$3.28$3.28$3.28
(Data provided by Zacks Investment Research)

Dividends

Dividend History for United Therapeutics Corporation (NASDAQ:UTHR)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for United Therapeutics Corporation (NASDAQ:UTHR)
Insider Ownership Percentage: 7.80%
Insider Trades by Quarter for United Therapeutics Corporation (NASDAQ:UTHR)
Institutional Ownership by Quarter for United Therapeutics Corporation (NASDAQ:UTHR)
Insider Trades by Quarter for United Therapeutics Corporation (NASDAQ:UTHR)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/21/2017Martine A RothblattCEOSell1,274$116.07$147,873.18View SEC Filing  
9/14/2017Martine A RothblattCEOSell1,258$122.08$153,576.64View SEC Filing  
9/7/2017Christopher CauseyDirectorSell580$134.48$77,998.40View SEC Filing  
9/7/2017Martine A RothblattCEOSell1,232$133.32$164,250.24View SEC Filing  
8/31/2017Martine A RothblattCEOSell1,235$130.49$161,155.15View SEC Filing  
8/24/2017Martine A RothblattCEOSell1,238$130.65$161,744.70View SEC Filing  
8/17/2017Martine A RothblattCEOSell1,235$131.95$162,958.25View SEC Filing  
8/10/2017Martine A RothblattCEOSell2,176$127.11$276,591.36View SEC Filing  
8/3/2017Martine A RothblattCEOSell1,248$126.41$157,759.68View SEC Filing  
7/27/2017Martine A RothblattCEOSell1,247$126.40$157,620.80View SEC Filing  
7/20/2017Martine A RothblattCEOSell1,236$131.62$162,682.32View SEC Filing  
7/13/2017Martine A RothblattCEOSell1,238$130.44$161,484.72View SEC Filing  
7/6/2017Christopher CauseyDirectorSell590$132.61$78,239.90View SEC Filing  
7/6/2017Martine A RothblattCEOSell1,234$132.29$163,245.86View SEC Filing  
7/5/2017Richard GiltnerDirectorSell3,490$131.12$457,608.80View SEC Filing  
6/29/2017Martine A RothblattCEOSell1,237$130.92$161,948.04View SEC Filing  
6/23/2017Raymond DwekDirectorSell3,490$131.71$459,667.90View SEC Filing  
6/22/2017Martine A RothblattCEOSell1,234$132.32$163,282.88View SEC Filing  
6/15/2017Martine A RothblattCEOSell1,238$130.20$161,187.60View SEC Filing  
6/8/2017Martine A RothblattCEOSell1,240$129.60$160,704.00View SEC Filing  
6/1/2017Martine A RothblattCEOSell1,251$125.02$156,400.02View SEC Filing  
5/25/2017Martine A RothblattCEOSell1,265$119.40$151,041.00View SEC Filing  
5/18/2017Martine A RothblattCEOSell1,261$120.72$152,227.92View SEC Filing  
5/11/2017Martine A RothblattCEOSell1,259$122.00$153,598.00View SEC Filing  
5/4/2017Martine A RothblattCEOSell1,258$122.24$153,777.92View SEC Filing  
4/27/2017Martine A RothblattCEOSell1,262$120.78$152,424.36View SEC Filing  
4/20/2017Martine A RothblattCEOSell1,260$121.14$152,636.40View SEC Filing  
4/13/2017Martine A RothblattCEOSell1,258$122.12$153,626.96View SEC Filing  
4/6/2017Martine A RothblattCEOSell1,257$122.39$153,844.23View SEC Filing  
3/30/2017Martine A RothblattCEOSell1,230$134.56$165,508.80View SEC Filing  
3/23/2017Martine A RothblattCEOSell1,219$139.33$169,843.27View SEC Filing  
3/22/2017Tommy G ThompsonDirectorSell2,000$139.37$278,740.00View SEC Filing  
3/16/2017Martine A RothblattCEOSell1,218$140.16$170,714.88View SEC Filing  
3/9/2017Martine A RothblattCEOSell1,206$146.72$176,944.32View SEC Filing  
3/2/2017Martine A RothblattCEOSell1,203$148.49$178,633.47View SEC Filing  
2/23/2017Martine A RothblattCEOSell1,208$145.16$175,353.28View SEC Filing  
2/16/2017Martine A RothblattCEOSell1,173$167.92$196,970.16View SEC Filing  
1/12/2017Christopher PatuskyDirectorSell5,000$141.99$709,950.00View SEC Filing  
1/12/2017Martine A RothblattCEOSell1,214$142.37$172,837.18View SEC Filing  
1/5/2017Martine A RothblattCEOSell1,208$145.73$176,041.84View SEC Filing  
12/29/2016Martine A RothblattCEOSell1,211$143.63$173,935.93View SEC Filing  
12/22/2016Martine A RothblattCEOSell1,218$140.23$170,800.14View SEC Filing  
12/15/2016Martine A RothblattCEOSell1,212$143.11$173,449.32View SEC Filing  
12/8/2016Martine A RothblattCEOSell1,236$131.78$162,880.08View SEC Filing  
12/6/2016Richard GiltnerDirectorSell5,000$133.37$666,850.00View SEC Filing  
12/1/2016Martine A RothblattCEOSell1,246$126.86$158,067.56View SEC Filing  
11/25/2016Martine A RothblattCEOSell1,233$132.81$163,754.73View SEC Filing  
11/17/2016Martine A RothblattCEOSell1,232$132.94$163,782.08View SEC Filing  
11/10/2016Christopher PatuskyDirectorSell5,000$131.42$657,100.00View SEC Filing  
11/10/2016Martine A RothblattCEOSell1,240$129.82$160,976.80View SEC Filing  
11/3/2016Martine A RothblattCEOSell1,272$116.94$148,747.68View SEC Filing  
10/27/2016Martine A RothblattCEOSell1,272$117.06$148,900.32View SEC Filing  
10/20/2016Martine A RothblattCEOSell1,282$113.30$145,250.60View SEC Filing  
10/13/2016Martine A RothblattCEOSell1,269$117.99$149,729.31View SEC Filing  
10/6/2016Martine A RothblattCEOSell1,260$121.17$152,674.20View SEC Filing  
9/29/2016Martine A RothblattCEOSell1,272$116.94$148,747.68View SEC Filing  
9/26/2016Tommy G ThompsonDirectorSell1,291$125.57$162,110.87View SEC Filing  
9/22/2016Martine A RothblattCEOSell1,249$125.87$157,211.63View SEC Filing  
9/15/2016Martine A RothblattCEOSell1,258$122.34$153,903.72View SEC Filing  
9/8/2016Martine A RothblattCEOSell1,254$123.44$154,793.76View SEC Filing  
9/1/2016Christopher PatuskyDirectorSell5,000$122.73$613,650.00View SEC Filing  
9/1/2016Martine A RothblattCEOSell1,257$122.81$154,372.17View SEC Filing  
8/25/2016Martine A RothblattCEOSell1,250$125.29$156,612.50View SEC Filing  
8/18/2016Martine A RothblattCEOSell1,249$125.88$157,224.12View SEC Filing  
8/11/2016Martine A RothblattCEOSell1,253$124.09$155,484.77View SEC Filing  
8/4/2016Martine A RothblattCEOSell1,249$125.78$157,099.22View SEC Filing  
7/28/2016Martine A RothblattCEOSell1,271$117.05$148,770.55View SEC Filing  
7/21/2016Martine A RothblattCEOSell1,284$112.77$144,796.68View SEC Filing  
7/14/2016Martine A RothblattCEOSell1,292$110.05$142,184.60View SEC Filing  
7/7/2016Martine A RothblattCEOSell1,293$109.87$142,061.91View SEC Filing  
6/30/2016Martine A RothblattCEOSell1,308$105.10$137,470.80View SEC Filing  
6/23/2016Martine A RothblattCEOSell1,312$104.07$136,539.84View SEC Filing  
6/16/2016Martine A RothblattCEOSell1,308$105.18$137,575.44View SEC Filing  
6/9/2016Martine A RothblattCEOSell1,277$114.99$146,842.23View SEC Filing  
6/8/2016Tommy G ThompsonDirectorSell2,000$115.62$231,240.00View SEC Filing  
6/2/2016Martine A RothblattCEOSell1,261$120.79$152,316.19View SEC Filing  
6/2/2016Raymond DwekDirectorSell3,000$118.82$356,460.00View SEC Filing  
5/26/2016Martine A RothblattCEOSell5,547$117.57$652,160.79View SEC Filing  
5/19/2016Martine A RothblattCEOSell5,546$110.75$614,219.50View SEC Filing  
5/12/2016Martine A RothblattCEOSell5,547$109.02$604,733.94View SEC Filing  
5/12/2016Raymond DwekDirectorSell3,000$110.00$330,000.00View SEC Filing  
5/5/2016Martine A RothblattCEOSell5,546$107.79$597,803.34View SEC Filing  
4/28/2016Martine A RothblattCEOSell5,547$106.81$592,475.07View SEC Filing  
4/21/2016Martine A RothblattCEOSell5,546$115.74$641,894.04View SEC Filing  
4/14/2016Martine A RothblattCEOSell5,547$114.32$634,133.04View SEC Filing  
4/7/2016Martine A RothblattCEOSell5,546$113.31$628,417.26View SEC Filing  
3/24/2016Martine A RothblattCEOSell5,546$110.80$614,496.80View SEC Filing  
3/17/2016Martine A RothblattCEOSell5,547$118.22$655,766.34View SEC Filing  
3/10/2016Martine A RothblattCEOSell5,546$123.41$684,431.86View SEC Filing  
3/3/2016Martine A RothblattCEOSell5,547$126.78$703,248.66View SEC Filing  
2/25/2016Martine A RothblattCEOSell5,546$122.45$679,107.70View SEC Filing  
2/18/2016Martine A RothblattCEOSell5,547$128.26$711,458.22View SEC Filing  
2/11/2016Martine A. RothblattCEOSell5,546$120.47$668,126.62View SEC Filing  
2/4/2016Martine A. RothblattCEOSell5,547$122.13$677,455.11View SEC Filing  
2/4/2016Raymond DwekDirectorSell3,000$122.66$367,980.00View SEC Filing  
1/28/2016Martine A. RothblattCEOSell5,546$124.00$687,704.00View SEC Filing  
1/21/2016Martine A. RothblattCEOSell5,547$127.00$704,469.00View SEC Filing  
1/14/2016Martine A. RothblattCEOSell5,546$135.94$753,923.24View SEC Filing  
1/7/2016Martine A. RothblattCEOSell5,547$145.84$808,974.48View SEC Filing  
1/7/2016Raymond DwekDirectorSell3,000$143.75$431,250.00View SEC Filing  
12/24/2015Martine A. RothblattCEOSell5,546$159.58$885,030.68View SEC Filing  
12/17/2015Martine A. RothblattCEOSell5,546$158.49$878,985.54View SEC Filing  
12/10/2015Martine A. RothblattCEOSell5,546$154.49$856,801.54View SEC Filing  
12/3/2015Martine A. RothblattCEOSell5,546$154.49$856,801.54View SEC Filing  
12/3/2015Raymond DwekDirectorSell3,000$157.22$471,660.00View SEC Filing  
11/27/2015Martine A. RothblattCEOSell5,561$153.81$855,337.41View SEC Filing  
11/19/2015Martine A. RothblattCEOSell9,661$148.56$1,435,238.16View SEC Filing  
11/12/2015Martine A. RothblattCEOSell4,115$147.72$607,867.80View SEC Filing  
11/5/2015Martine A. RothblattCEOSell4,115$149.16$613,793.40View SEC Filing  
11/5/2015Raymond DwekDirectorSell3,000$149.63$448,890.00View SEC Filing  
11/3/2015Richard GiltnerDirectorSell7,500$153.22$1,149,150.00View SEC Filing  
10/29/2015Martine A. RothblattCEOSell9,662$141.89$1,370,941.18View SEC Filing  
10/28/2015Martine A. RothblattCEOSell2,211$136.58$301,978.38View SEC Filing  
10/26/2015Martine A. RothblattCEOSell2,592$127.13$329,520.96View SEC Filing  
10/22/2015Martine A. RothblattCEOSell9,662$122.40$1,182,628.80View SEC Filing  
10/21/2015Martine A. RothblattCEOSell2,211$123.63$273,345.93View SEC Filing  
10/19/2015Martine A. RothblattCEOSell2,592$126.71$328,432.32View SEC Filing  
10/15/2015Martine A. RothblattCEOSell9,662$126.22$1,219,537.64View SEC Filing  
10/14/2015Martine A. RothblattCEOSell2,211$123.53$273,124.83View SEC Filing  
10/12/2015Martine A. RothblattCEOSell2,592$123.51$320,137.92View SEC Filing  
10/8/2015Martine A. RothblattCEOSell9,662$122.48$1,183,401.76View SEC Filing  
10/7/2015Martine A. RothblattCEOSell2,211$120.88$267,265.68View SEC Filing  
10/5/2015Martine A. RothblattCEOSell2,592$126.88$328,872.96View SEC Filing  
10/1/2015Martine A. RothblattCEOSell6,326$131.11$829,401.86View SEC Filing  
10/1/2015Paul A. MahonEVPSell6,000$129.38$776,280.00View SEC Filing  
10/1/2015Raymond DwekDirectorSell3,000$131.32$393,960.00View SEC Filing  
9/29/2015Martine A. RothblattCEOSell2,592$134.25$347,976.00View SEC Filing  
9/29/2015Tommy G. ThompsonDirectorSell5,000$139.19$695,950.00View SEC Filing  
9/24/2015Martine A. RothblattCEOSell9,662$139.26$1,345,530.12View SEC Filing  
9/23/2015Martine A. RothblattCEOSell2,211$142.05$314,072.55View SEC Filing  
9/21/2015Martine A. RothblattCEOSell2,592$150.81$390,899.52View SEC Filing  
9/17/2015Martine A. RothblattCEOSell9,662$152.02$1,468,817.24View SEC Filing  
9/16/2015Martine A. RothblattCEOSell2,211$151.93$335,917.23View SEC Filing  
9/14/2015Martine A. RothblattCEOSell2,592$153.08$396,783.36View SEC Filing  
9/10/2015Martine A. RothblattCEOSell4,115$152.95$629,389.25View SEC Filing  
9/9/2015Martine A. RothblattCEOSell2,211$152.77$337,774.47View SEC Filing  
9/8/2015Martine A. RothblattCEOSell2,592$152.80$396,057.60View SEC Filing  
9/3/2015Martine A. RothblattCEOSell9,662$153.67$1,484,759.54View SEC Filing  
9/3/2015Raymond DwekDirectorSell3,000$155.54$466,620.00View SEC Filing  
9/2/2015Martine A. RothblattCEOSell2,211$151.12$334,126.32View SEC Filing  
8/31/2015Martine A. RothblattCEOSell2,592$153.50$397,872.00View SEC Filing  
8/27/2015Martine A. RothblattCEOSell9,662$160.37$1,549,494.94View SEC Filing  
8/26/2015Martine A. RothblattCEOSell2,211$155.47$343,744.17View SEC Filing  
8/24/2015Martine A. RothblattCEOSell2,592$155.36$402,693.12View SEC Filing  
8/20/2015Martine A. RothblattCEOSell9,662$166.58$1,609,495.96View SEC Filing  
8/19/2015Martine A. RothblattCEOSell2,211$167.13$369,524.43View SEC Filing  
8/17/2015Martine A RothblattCEOSell2,592$166.61$431,853.12View SEC Filing  
8/13/2015Martine A RothblattCEOSell9,662$165.05$1,594,713.10View SEC Filing  
7/27/2015Martine A RothblattCEOSell2,592$166.38$431,256.96View SEC Filing  
7/23/2015Martine A RothblattCEOSell4,115$176.38$725,803.70View SEC Filing  
7/22/2015Martine A RothblattCEOSell2,211$174.55$385,930.05View SEC Filing  
7/20/2015Martine A RothblattCEOSell2,592$177.92$461,168.64View SEC Filing  
7/16/2015Martine A RothblattCEOSell9,662$175.51$1,695,777.62View SEC Filing  
7/15/2015Martine A RothblattCEOSell2,211$176.77$390,838.47View SEC Filing  
7/13/2015Martine A RothblattCEOSell2,592$172.42$446,912.64View SEC Filing  
7/9/2015Martine A RothblattCEOSell9,662$168.04$1,623,602.48View SEC Filing  
7/8/2015Martine A RothblattCEOSell2,211$167.13$369,524.43View SEC Filing  
7/6/2015Martine A RothblattCEOSell2,592$170.66$442,350.72View SEC Filing  
7/2/2015Martine A RothblattCEOSell6,326$170.69$1,079,784.94View SEC Filing  
7/2/2015Raymond DwekDirectorSell3,000$171.59$514,770.00View SEC Filing  
6/29/2015Martine A RothblattCEOSell2,592$172.86$448,053.12View SEC Filing  
6/25/2015Martine A RothblattCEOSell9,662$176.91$1,709,304.42View SEC Filing  
6/24/2015Martine A RothblattCEOSell2,211$179.68$397,272.48View SEC Filing  
6/22/2015Martine A RothblattCEOSell2,592$188.64$488,954.88View SEC Filing  
6/18/2015Louis W SullivanDirectorSell15,000$185.60$2,784,000.00View SEC Filing  
6/18/2015Martine A RothblattCEOSell9,662$185.72$1,794,426.64View SEC Filing  
6/17/2015Martine A RothblattCEOSell2,211$185.25$409,587.75View SEC Filing  
6/15/2015Martine A RothblattCEOSell2,592$185.15$479,908.80View SEC Filing  
6/11/2015Martine A RothblattCEOSell9,662$183.76$1,775,489.12View SEC Filing  
6/10/2015Martine A RothblattCEOSell2,211$180.87$399,903.57View SEC Filing  
6/8/2015Martine A RothblattCEOSell2,592$181.34$470,033.28View SEC Filing  
6/4/2015Martine A RothblattCEOSell9,662$181.94$1,757,904.28View SEC Filing  
6/4/2015Raymond DwekDirectorSell3,000$181.36$544,080.00View SEC Filing  
6/3/2015Martine A RothblattCEOSell2,211$184.49$407,907.39View SEC Filing  
6/1/2015Martine A RothblattCEOSell2,592$182.66$473,454.72View SEC Filing  
5/28/2015Martine A RothblattCEOSell9,662$180.88$1,747,662.56View SEC Filing  
5/27/2015Martine A RothblattCEOSell2,211$184.39$407,686.29View SEC Filing  
5/26/2015Martine A RothblattCEOSell2,592$182.64$473,402.88View SEC Filing  
5/21/2015Martine A RothblattCEOSell9,662$182.44$1,762,735.28View SEC Filing  
5/21/2015Tommy G ThompsonDirectorSell1,500$182.04$273,060.00View SEC Filing  
5/20/2015Martine A RothblattCEOSell2,211$182.80$404,170.80View SEC Filing  
5/18/2015Martine A RothblattCEOSell2,592$177.79$460,831.68View SEC Filing  
5/14/2015Martine A RothblattCEOSell9,662$174.07$1,681,864.34View SEC Filing  
5/13/2015Martine A RothblattCEOSell2,211$175.41$387,831.51View SEC Filing  
5/11/2015Martine A RothblattCEOSell2,592$179.55$465,393.60View SEC Filing  
5/7/2015Christopher CauseyDirectorSell1,500$167.94$251,910.00View SEC Filing  
5/7/2015Martine A RothblattCEOSell9,662$169.86$1,641,187.32View SEC Filing  
5/6/2015Martine A RothblattCEOSell2,211$169.22$374,145.42View SEC Filing  
5/4/2015Martine A RothblattCEOSell2,592$169.81$440,147.52View SEC Filing  
5/1/2015Raymond DwekDirectorSell3,000$159.58$478,740.00View SEC Filing  
4/30/2015Martine A RothblattCEOSell9,662$162.36$1,568,722.32View SEC Filing  
4/29/2015Martine A RothblattCEOSell2,211$164.29$363,245.19View SEC Filing  
4/28/2015Roger JeffsCEOSell5,000$163.31$816,550.00View SEC Filing  
4/27/2015Martine A RothblattCEOSell2,592$177.62$460,391.04View SEC Filing  
4/23/2015Martine A RothblattCEOSell9,662$187.35$1,810,175.70View SEC Filing  
4/22/2015Martine A RothblattCEOSell2,211$187.49$414,540.39View SEC Filing  
4/21/2015Roger JeffsCEOSell10,000$187.86$1,878,600.00View SEC Filing  
4/20/2015Martine A RothblattCEOSell2,592$184.86$479,157.12View SEC Filing  
4/16/2015Martine A RothblattCEOSell11,873$187.01$2,220,369.73View SEC Filing  
4/16/2015Paul A MahonEVPSell6,000$187.91$1,127,460.00View SEC Filing  
4/14/2015David ZaccardelliCOOSell3,250$185.82$603,915.00View SEC Filing  
4/14/2015Roger JeffsCEOSell10,000$185.82$1,858,200.00View SEC Filing  
4/13/2015Martine A RothblattCEOSell2,592$187.86$486,933.12View SEC Filing  
4/9/2015David ZaccardelliCOOSell4,000$184.84$739,360.00View SEC Filing  
4/9/2015Martine A RothblattCEOSell9,662$183.09$1,769,015.58View SEC Filing  
4/8/2015Martine A RothblattCEOSell2,211$181.91$402,203.01View SEC Filing  
4/7/2015David ZaccardelliCOOSell4,000$179.34$717,360.00View SEC Filing  
4/7/2015Roger JeffsCEOSell10,000$179.34$1,793,400.00View SEC Filing  
4/6/2015Martine A RothblattCEOSell2,592$176.20$456,710.40View SEC Filing  
4/2/2015David ZaccardelliCOOSell4,000$174.73$698,920.00View SEC Filing  
4/2/2015Martine A RothblattCEOSell11,873$173.43$2,059,134.39View SEC Filing  
4/2/2015Paul A MahonEVPSell6,000$174.73$1,048,380.00View SEC Filing  
4/2/2015Raymond DwekDirectorSell3,000$175.49$526,470.00View SEC Filing  
3/30/2015Martine A RothblattCEOSell2,592$177.22$459,354.24View SEC Filing  
3/26/2015David ZaccardelliCOOSell4,000$167.52$670,080.00View SEC Filing  
3/26/2015Martine A RothblattCEOSell9,662$167.03$1,613,843.86View SEC Filing  
3/25/2015Martine A RothblattCEOSell2,211$173.67$383,984.37View SEC Filing  
3/24/2015David ZaccardelliCOOSell4,500$179.51$807,795.00View SEC Filing  
3/23/2015Martine A RothblattCEOSell2,592$177.76$460,753.92View SEC Filing  
3/19/2015Paul A MahonEVPSell6,000$175.82$1,054,920.00View SEC Filing  
3/18/2015Martine A RothblattCEOSell2,211$174.64$386,129.04View SEC Filing  
3/17/2015David ZaccardelliCOOSell4,000$177.34$709,360.00View SEC Filing  
3/16/2015Martine A RothblattCEOSell2,592$170.97$443,154.24View SEC Filing  
3/12/2015Martine A RothblattCEOSell11,873$162.94$1,934,586.62View SEC Filing  
3/10/2015Roger JeffsCEOSell18,750$143.68$2,694,000.00View SEC Filing  
3/9/2015Martine A RothblattCEOSell2,592$160.51$416,041.92View SEC Filing  
3/5/2015Martine A RothblattCEOSell9,662$159.75$1,543,504.50View SEC Filing  
3/5/2015Raymond DwekDirectorSell3,000$157.59$472,770.00View SEC Filing  
3/4/2015Martine A RothblattCEOSell2,211$157.63$348,519.93View SEC Filing  
3/3/2015Roger JeffsCEOSell10,000$157.74$1,577,400.00View SEC Filing  
3/2/2015Martine A RothblattCEOSell2,592$155.32$402,589.44View SEC Filing  
2/27/2015Ray KurzweilDirectorSell15,000$155.05$2,325,750.00View SEC Filing  
2/26/2015Martine A RothblattCEOSell9,662$155.23$1,499,832.26View SEC Filing  
2/25/2015Martine A RothblattCEOSell2,211$159.35$352,322.85View SEC Filing  
2/24/2015David ZaccardelliCOOSell1,458$155.16$226,223.28View SEC Filing  
2/24/2015Roger JeffsCEOSell10,000$155.16$1,551,600.00View SEC Filing  
2/23/2015Martine A RothblattCEOSell2,592$156.08$404,559.36View SEC Filing  
2/19/2015John Maxim FerrariCFOSell10,000$155.72$1,557,200.00View SEC Filing  
2/19/2015Martine A RothblattCEOSell9,662$155.99$1,507,175.38View SEC Filing  
2/19/2015Paul A MahonEVPSell6,000$155.72$934,320.00View SEC Filing  
2/17/2015David ZaccardelliCOOSell4,000$155.14$620,560.00View SEC Filing  
2/17/2015Martine A RothblattCEOSell2,592$152.28$394,709.76View SEC Filing  
2/12/2015Martine A RothblattCEOSell9,662$146.01$1,410,748.62View SEC Filing  
2/11/2015Martine A RothblattCEOSell2,211$147.29$325,658.19View SEC Filing  
2/10/2015David ZaccardelliCOOSell4,000$146.68$586,720.00View SEC Filing  
2/10/2015Roger JeffsCEOSell10,000$146.68$1,466,800.00View SEC Filing  
2/9/2015Martine A RothblattCEOSell2,592$143.32$371,485.44View SEC Filing  
2/5/2015John Maxim FerrariCFOSell10,000$141.92$1,419,200.00View SEC Filing  
2/5/2015Martine A RothblattCEOSell11,773$141.07$1,660,817.11View SEC Filing  
2/5/2015Paul A MahonEVPSell6,000$141.92$851,520.00View SEC Filing  
2/5/2015Raymond DwekDirectorSell3,000$140.41$421,230.00View SEC Filing  
2/3/2015David ZaccardelliCOOSell4,000$141.99$567,960.00View SEC Filing  
2/3/2015Roger JeffsCEOSell10,000$141.99$1,419,900.00View SEC Filing  
1/29/2015Martine A RothblattCEOSell9,662$143.29$1,384,467.98View SEC Filing  
1/28/2015Martine A RothblattCEOSell2,211$145.49$321,678.39View SEC Filing  
1/27/2015David ZaccardelliCOOSell4,000$147.19$588,760.00View SEC Filing  
1/27/2015Roger JeffsCEOSell10,000$147.19$1,471,900.00View SEC Filing  
1/26/2015Martine A RothblattCEOSell2,592$145.89$378,146.88View SEC Filing  
1/22/2015Martine A RothblattCEOSell11,873$146.76$1,742,481.48View SEC Filing  
1/20/2015David ZaccardelliCOOSell4,000$146.48$585,920.00View SEC Filing  
1/20/2015Martine A RothblattCEOSell2,592$145.06$375,995.52View SEC Filing  
1/15/2015John Maxim FerrariCFOSell22,500$137.84$3,101,400.00View SEC Filing  
1/15/2015Martine A RothblattCEOSell9,662$137.51$1,328,621.62View SEC Filing  
1/15/2015Paul A MahonEVPSell6,000$137.84$827,040.00View SEC Filing  
1/14/2015Martine A RothblattCEOSell2,211$135.18$298,882.98View SEC Filing  
1/13/2015David ZaccardelliCOOSell3,000$134.71$404,130.00View SEC Filing  
1/13/2015Roger JeffsCEOSell10,000$134.71$1,347,100.00View SEC Filing  
1/12/2015Martine A RothblattCEOSell2,592$132.00$342,144.00View SEC Filing  
1/8/2015Christopher PatuskyDirectorSell5,000$128.13$640,650.00View SEC Filing  
1/8/2015Martine A RothblattCEOSell9,662$128.31$1,239,731.22View SEC Filing  
1/7/2015Martine A RothblattCEOSell2,211$126.04$278,674.44View SEC Filing  
1/6/2015David ZaccardelliCOOSell3,000$124.93$374,790.00View SEC Filing  
1/6/2015Roger JeffsCEOSell7,500$124.93$936,975.00View SEC Filing  
1/5/2015Martine A RothblattCEOSell2,592$126.88$328,872.96View SEC Filing  
1/2/2015Christopher CauseyDirectorSell3,000$129.25$387,750.00View SEC Filing  
1/2/2015Martine A RothblattCEOSell9,662$126.53$1,222,532.86View SEC Filing  
1/2/2015Paul A MahonEVPSell6,000$127.73$766,380.00View SEC Filing  
12/31/2014Martine A RothblattCEOSell2,211$131.35$290,414.85View SEC Filing  
12/30/2014Roger JeffsCEOSell10,000$130.80$1,308,000.00View SEC Filing  
12/29/2014Martine A RothblattCEOSell2,592$131.75$341,496.00View SEC Filing  
12/26/2014Martine A RothblattCEOSell9,662$131.85$1,273,934.70View SEC Filing  
12/24/2014Martine A RothblattCEOSell2,211$130.35$288,203.85View SEC Filing  
12/23/2014Roger JeffsCOOSell10,000$127.82$1,278,200.00View SEC Filing  
12/22/2014Martine A RothblattCEOSell2,592$133.45$345,902.40View SEC Filing  
12/19/2014Christopher CauseyDirectorSell1,500$131.47$197,205.00View SEC Filing  
12/18/2014John Maxim FerrariCFOSell10,000$131.11$1,311,100.00View SEC Filing  
12/18/2014Martine A RothblattCEOSell9,662$129.06$1,246,977.72View SEC Filing  
12/18/2014Paul A MahonEVPSell10,750$130.03$1,397,822.50View SEC Filing  
12/17/2014Martine A RothblattCEOSell2,211$126.04$278,674.44View SEC Filing  
12/15/2014Martine A RothblattCEOSell2,592$129.75$336,312.00View SEC Filing  
12/11/2014Martine A RothblattCEOSell9,662$130.98$1,265,528.76View SEC Filing  
12/10/2014Martine A RothblattCEOSell2,211$132.77$293,554.47View SEC Filing  
12/9/2014Roger JeffsCOOSell10,000$134.80$1,348,000.00View SEC Filing  
12/8/2014Martine A RothblattCEOSell2,592$132.34$343,025.28View SEC Filing  
12/4/2014John Maxim FerrariCFOSell10,000$129.05$1,290,500.00View SEC Filing  
12/4/2014Martine A RothblattCEOSell11,873$131.32$1,559,162.36View SEC Filing  
12/4/2014Paul A MahonEVPSell11,000$129.92$1,429,120.00View SEC Filing  
12/4/2014Raymond DwekDirectorSell3,000$131.58$394,740.00View SEC Filing  
12/2/2014Roger JeffsCOOSell10,000$133.63$1,336,300.00View SEC Filing  
12/1/2014Martine A RothblattCEOSell2,592$132.92$344,528.64View SEC Filing  
11/28/2014Martine A RothblattCEOSell11,873$132.77$1,576,378.21View SEC Filing  
11/25/2014Roger JeffsCOOSell10,000$131.30$1,313,000.00View SEC Filing  
11/24/2014Martine A RothblattCEOSell2,592$130.72$338,826.24View SEC Filing  
11/21/2014Roger JeffsCOOSell10,000$130.15$1,301,500.00View SEC Filing  
11/20/2014Christopher CauseyDirectorSell1,500$127.20$190,800.00View SEC Filing  
11/20/2014John Maxim FerrariCFOSell10,000$129.22$1,292,200.00View SEC Filing  
11/20/2014Martine A RothblattCEOSell9,662$128.86$1,245,045.32View SEC Filing  
11/20/2014Paul A MahonEVPSell11,000$129.02$1,419,220.00View SEC Filing  
11/19/2014Martine A RothblattCEOSell2,211$128.69$284,533.59View SEC Filing  
11/18/2014Roger JeffsCOOSell10,000$128.21$1,282,100.00View SEC Filing  
11/17/2014Martine A RothblattCEOSell2,592$125.65$325,684.80View SEC Filing  
11/13/2014Martine A RothblattCEOSell9,662$124.79$1,205,720.98View SEC Filing  
11/12/2014Martine A RothblattCEOSell2,211$122.88$271,687.68View SEC Filing  
11/10/2014Martine A RothblattCEOSell2,592$125.14$324,362.88View SEC Filing  
11/7/2014Christopher PatuskyDirectorSell5,000$124.49$622,450.00View SEC Filing  
11/7/2014Roger JeffsCOOSell10,000$124.46$1,244,600.00View SEC Filing  
11/6/2014Christopher CauseyDirectorSell1,500$122.89$184,335.00View SEC Filing  
11/6/2014Martine A RothblattCEOSell4,115$125.33$515,732.95View SEC Filing  
11/6/2014Paul A MahonEVPSell5,000$125.02$625,100.00View SEC Filing  
11/5/2014Martine A RothblattCEOSell2,211$124.31$274,849.41View SEC Filing  
11/3/2014Martine A RothblattCEOSell2,592$127.49$330,454.08View SEC Filing  
10/30/2014Martine A RothblattCEOSell9,662$130.42$1,260,118.04View SEC Filing  
10/29/2014Martine A RothblattCEOSell2,211$131.10$289,862.10View SEC Filing  
10/27/2014Martine A RothblattCEOSell2,592$132.16$342,558.72View SEC Filing  
10/23/2014Martine A RothblattCEOSell11,873$129.97$1,543,133.81View SEC Filing  
10/23/2014Paul A MahonEVPSell11,000$127.04$1,397,440.00View SEC Filing  
10/13/2014Martine A RothblattCEOSell2,592$124.31$322,211.52View SEC Filing  
10/9/2014Martine A RothblattCEOSell9,662$129.97$1,255,770.14View SEC Filing  
10/9/2014Paul A MahonEVPSell5,000$130.59$652,950.00View SEC Filing  
10/8/2014Martine A RothblattCEOSell2,211$131.50$290,746.50View SEC Filing  
10/7/2014Roger JeffsCOOSell35,000$130.14$4,554,900.00View SEC Filing  
10/6/2014Martine A RothblattCEOSell2,592$129.32$335,197.44View SEC Filing  
10/3/2014Roger JeffsCOOSell10,000$129.79$1,297,900.00View SEC Filing  
10/2/2014Christopher CauseyDirectorSell1,500$130.65$195,975.00View SEC Filing  
10/2/2014John Maxim FerrariCFOSell10,000$129.46$1,294,600.00View SEC Filing  
10/2/2014Martine A RothblattCEOSell9,662$127.72$1,234,030.64View SEC Filing  
10/2/2014Paul A MahonEVPSell6,000$129.46$776,760.00View SEC Filing  
10/1/2014Martine A RothblattCEOSell2,211$127.40$281,681.40View SEC Filing  
9/30/2014Roger JeffsCOOSell20,000$128.65$2,573,000.00View SEC Filing  
9/25/2014Martine A RothblattCEOSell5,547$134.26$744,740.22View SEC Filing  
9/25/2014Paul A MahonEVPSell5,000$133.77$668,850.00View SEC Filing  
9/25/2014Richard GiltnerDirectorSell20,000$134.94$2,698,800.00View SEC Filing  
9/23/2014Roger JeffsCOOSell50,000$131.02$6,551,000.00View SEC Filing  
9/19/2014Roger JeffsCOOSell10,000$129.60$1,296,000.00View SEC Filing  
9/18/2014John Maxim FerrariCFOSell10,000$130.93$1,309,300.00View SEC Filing  
9/18/2014Martine A RothblattCEOSell9,662$127.35$1,230,455.70View SEC Filing  
9/18/2014Paul A MahonEVPSell6,000$130.93$785,580.00View SEC Filing  
9/17/2014Roger JeffsCOOSell20,000$127.01$2,540,200.00View SEC Filing  
9/15/2014Martine A RothblattCEOSell50,000$124.52$6,226,000.00View SEC Filing  
9/11/2014Martine A RothblattCEOSell9,662$120.79$1,167,072.98View SEC Filing  
9/11/2014Paul A MahonEVPSell5,000$120.70$603,500.00View SEC Filing  
9/10/2014Martine A RothblattCEOSell50,000$120.01$6,000,500.00View SEC Filing  
9/10/2014Richard GiltnerDirectorSell20,000$119.95$2,399,000.00View SEC Filing  
9/5/2014Roger JeffsCOOSell10,000$111.29$1,112,900.00View SEC Filing  
9/4/2014John Maxim FerrariCFOSell10,000$112.38$1,123,800.00View SEC Filing  
9/4/2014Martine A RothblattCEOSell9,662$112.87$1,090,549.94View SEC Filing  
9/4/2014Paul A MahonEVPSell6,000$112.38$674,280.00View SEC Filing  
9/4/2014Raymond DwekDirectorSell3,000$113.40$340,200.00View SEC Filing  
8/28/2014Martine A RothblattCEOSell7,014$92.46$648,514.44View SEC Filing  
8/28/2014Paul A MahonEVPSell5,000$92.07$460,350.00View SEC Filing  
8/21/2014John Maxim FerrariCFOSell10,000$93.75$937,500.00View SEC Filing  
8/21/2014Martine A RothblattCEOSell9,640$93.13$897,773.20View SEC Filing  
8/15/2014Christopher CauseyDirectorSell1,500$91.14$136,710.00View SEC Filing  
8/14/2014Martine A RothblattCEOSell4,115$88.39$363,724.85View SEC Filing  
8/14/2014Paul A MahonEVPSell10,000$88.41$884,100.00View SEC Filing  
8/7/2014Christopher PatuskyDirectorSell5,000$88.23$441,150.00View SEC Filing  
8/7/2014John Maxim FerrariCFOSell10,000$86.44$864,400.00View SEC Filing  
8/7/2014Martine A RothblattCEOSell4,115$88.40$363,766.00View SEC Filing  
8/1/2014Raymond DwekDirectorSell3,000$89.52$268,560.00View SEC Filing  
8/1/2014Roger JeffsCOOSell10,000$89.88$898,800.00View SEC Filing  
7/31/2014Martine A RothblattCEOSell3,933$90.95$357,706.35View SEC Filing  
7/29/2014Roger JeffsCOOSell50,000$96.25$4,812,500.00View SEC Filing  
7/25/2014Roger JeffsCOOSell10,000$91.54$915,400.00View SEC Filing  
7/24/2014Martine A RothblattCEOSell9,228$93.15$859,588.20View SEC Filing  
7/17/2014John Maxim FerrariCFOSell10,000$89.74$897,400.00View SEC Filing  
7/17/2014Martine A RothblattCEOSell3,833$90.87$348,304.71View SEC Filing  
7/11/2014Roger JeffsCOOSell10,000$93.06$930,600.00View SEC Filing  
7/10/2014Martine A RothblattCEOSell9,187$92.33$848,235.71View SEC Filing  
7/3/2014Christopher CauseyDirectorSell1,500$91.62$137,430.00View SEC Filing  
7/3/2014John Maxim FerrariCFOSell10,000$90.58$905,800.00View SEC Filing  
7/3/2014Martine A RothblattCEOSell3,833$91.37$350,221.21View SEC Filing  
6/26/2014Martine A RothblattCEOSell3,833$87.23$334,352.59View SEC Filing  
6/20/2014Roger JeffsCOOSell10,000$87.00$870,000.00View SEC Filing  
6/19/2014John Maxim FerrariCFOSell10,000$87.02$870,200.00View SEC Filing  
6/19/2014Martine A RothblattCEOSell3,833$85.68$328,411.44View SEC Filing  
6/19/2014Paul A MahonEVPSell2,000$85.67$171,340.00View SEC Filing  
6/12/2014Martine A RothblattCEOSell9,066$98.22$890,462.52View SEC Filing  
6/10/2014Roger JeffsCOOSell10,000$96.29$962,900.00View SEC Filing  
6/9/2014Roger JeffsCOOSell10,000$96.32$963,200.00View SEC Filing  
6/5/2014Christopher CauseyDirectorSell1,500$96.48$144,720.00View SEC Filing  
6/5/2014Martine A RothblattCEOSell9,066$96.46$874,506.36View SEC Filing  
6/5/2014Paul A MahonEVPSell6,000$96.50$579,000.00View SEC Filing  
6/3/2014Roger JeffsCOOSell10,000$95.00$950,000.00View SEC Filing  
5/29/2014Martine A RothblattCEOSell9,066$95.27$863,717.82View SEC Filing  
5/27/2014Roger JeffsCOOSell10,000$99.14$991,400.00View SEC Filing  
5/22/2014Louis SullivanDirectorSell30,000$101.46$3,043,800.00View SEC Filing  
5/22/2014Martine RothblattCEOSell9,066$101.35$918,839.10View SEC Filing  
5/20/2014Roger JeffsCOOSell10,000$99.91$999,100.00View SEC Filing  
5/16/2014Roger JeffsCOOSell10,000$100.00$1,000,000.00View SEC Filing  
5/15/2014John Maxim FerrariCFOSell10,000$101.49$1,014,900.00View SEC Filing  
5/15/2014Martine RothblattCEOSell9,066$100.88$914,578.08View SEC Filing  
5/15/2014Paul MahonEVPSell6,000$100.86$605,160.00View SEC Filing  
5/13/2014Roger JeffsCOOSell10,000$105.53$1,055,300.00View SEC Filing  
5/8/2014Christopher PatuskyDirectorSell5,000$107.17$535,850.00View SEC Filing  
5/8/2014Martine RothblattCEOSell9,066$107.83$977,586.78View SEC Filing  
5/6/2014Roger JeffsCOOSell10,000$106.50$1,065,000.00View SEC Filing  
5/2/2014Roger JeffsCOOSell10,000$102.00$1,020,000.00View SEC Filing  
5/1/2014Christopher CauseyDirectorSell1,500$99.30$148,950.00View SEC Filing  
5/1/2014John Maxim FerrariCFOSell10,000$102.20$1,022,000.00View SEC Filing  
5/1/2014Martine RothblattCEOSell9,066$101.84$923,281.44View SEC Filing  
5/1/2014Paul MahonEVPSell6,000$102.71$616,260.00View SEC Filing  
4/29/2014Roger JeffsCOOSell10,000$95.00$950,000.00View SEC Filing  
4/24/2014Martine RothblattCEOSell9,066$92.45$838,151.70View SEC Filing  
4/22/2014Roger JeffsCOOSell10,000$96.00$960,000.00View SEC Filing  
4/17/2014John Maxim FerrariCFOSell10,000$96.20$962,000.00View SEC Filing  
4/17/2014Martine RothblattCEOSell9,066$98.48$892,819.68View SEC Filing  
4/17/2014Paul MahonEVPSell6,000$98.37$590,220.00View SEC Filing  
4/15/2014Roger JeffsCOOSell10,000$95.06$950,600.00View SEC Filing  
4/10/2014Martine RothblattCEOSell9,066$96.18$871,967.88View SEC Filing  
4/8/2014Roger JeffsCOOSell10,000$95.00$950,000.00View SEC Filing  
4/4/2014Roger JeffsCOOSell10,000$93.22$932,200.00View SEC Filing  
4/3/2014Christopher CauseyDirectorSell1,500$95.67$143,505.00View SEC Filing  
4/3/2014John Maxim FerrariCFOSell10,000$93.22$932,200.00View SEC Filing  
4/3/2014Martine RothblattCEOSell9,066$93.74$849,846.84View SEC Filing  
4/3/2014Paul MahonEVPSell6,000$93.10$558,600.00View SEC Filing  
4/1/2014Roger JeffsCOOSell10,000$95.44$954,400.00View SEC Filing  
3/27/2014Martine RothblattCEOSell9,066$93.35$846,311.10View SEC Filing  
3/25/2014Roger JeffsCOOSell10,000$95.64$956,400.00View SEC Filing  
3/21/2014Roger JeffsCOOSell10,000$93.84$938,400.00View SEC Filing  
3/20/2014Christopher CauseyDirectorSell1,500$96.04$144,060.00View SEC Filing  
3/20/2014John Maxim FerrariCFOSell10,000$96.11$961,100.00View SEC Filing  
3/20/2014Martine RothblattCEOSell9,065$96.76$877,129.40View SEC Filing  
3/20/2014Paul MahonEVPSell6,000$96.81$580,860.00View SEC Filing  
3/18/2014Roger JeffsCOOSell10,000$96.51$965,100.00View SEC Filing  
3/13/2014Martine RothblattCEOSell3,833$95.64$366,588.12View SEC Filing  
3/7/2014Roger JeffsCOOSell10,000$99.02$990,200.00View SEC Filing  
3/6/2014Christopher PatuskyDirectorSell5,000$101.39$506,950.00View SEC Filing  
3/6/2014John Maxim FerrariCFOSell10,000$99.07$990,700.00View SEC Filing  
3/6/2014Martine RothblattCEOSell3,833$102.77$393,917.41View SEC Filing  
3/6/2014Paul MahonEVPSell6,000$101.93$611,580.00View SEC Filing  
2/28/2014Ray KurzweilDirectorSell15,000$101.42$1,521,300.00View SEC Filing  
2/27/2014Martine RothblattCEOSell3,833$100.68$385,906.44View SEC Filing  
2/21/2014Roger JeffsCOOSell10,000$104.89$1,048,900.00View SEC Filing  
2/20/2014Martine RothblattCEOSell3,833$103.91$398,287.03View SEC Filing  
2/20/2014Paul MahonEVPSell6,000$104.63$627,780.00View SEC Filing  
2/13/2014Martine RothblattCEOSell3,833$99.87$382,801.71View SEC Filing  
2/7/2014Roger JeffsCOOSell10,000$96.61$966,100.00View SEC Filing  
2/6/2014Martine RothblattCEOSell3,833$97.26$372,797.58View SEC Filing  
2/6/2014Paul MahonEVPSell6,000$97.41$584,460.00View SEC Filing  
2/6/2014Raymond DwekDirectorSell3,000$97.33$291,990.00View SEC Filing  
1/30/2014Martine RothblattCEOSell3,833$106.25$407,256.25View SEC Filing  
1/23/2014Martine RothblattCEOSell3,833$111.78$428,452.74View SEC Filing  
1/17/2014Roger JeffsCOOSell10,000$113.03$1,130,300.00View SEC Filing  
1/16/2014Martine RothblattCEOSell3,833$111.21$426,267.93View SEC Filing  
1/16/2014Paul MahonEVPSell6,000$111.98$671,880.00View SEC Filing  
1/9/2014Christopher PatuskyDirectorSell5,000$110.00$550,000.00View SEC Filing  
1/9/2014Martine RothblattCEOSell3,833$108.35$415,305.55View SEC Filing  
1/3/2014Roger JeffsCOOSell10,000$110.72$1,107,200.00View SEC Filing  
1/2/2014Martine RothblattCEOSell3,833$111.54$427,532.82View SEC Filing  
1/2/2014Paul MahonEVPSell6,000$110.78$664,680.00View SEC Filing  
1/2/2014Raymond DwekDirectorSell3,000$111.41$334,230.00View SEC Filing  
12/31/2013Martine RothblattCEOSell18,140$112.64$2,043,289.60View SEC Filing  
12/30/2013Martine RothblattCEOSell18,147$111.60$2,025,205.20View SEC Filing  
12/27/2013Martine RothblattCEOSell18,147$113.15$2,053,333.05View SEC Filing  
12/26/2013Martine RothblattCEOSell21,981$111.95$2,460,772.95View SEC Filing  
12/24/2013Martine RothblattCEOSell18,149$114.05$2,069,893.45View SEC Filing  
12/23/2013Martine RothblattCEOSell5,743$109.71$630,064.53View SEC Filing  
12/20/2013Martine RothblattCEOSell18,149$86.72$1,573,881.28View SEC Filing  
12/20/2013Roger JeffsCOOSell8,250$87.84$724,680.00View SEC Filing  
12/19/2013Martine RothblattCEOSell21,982$86.73$1,906,498.86View SEC Filing  
12/19/2013Paul MahonEVPSell6,000$86.45$518,700.00View SEC Filing  
12/18/2013Martine RothblattCEOSell18,149$86.36$1,567,347.64View SEC Filing  
12/17/2013Martine RothblattCEOSell12,251$86.49$1,059,588.99View SEC Filing  
12/6/2013Roger JeffsCOOSell10,000$90.97$909,700.00View SEC Filing  
12/5/2013Martine RothblattCEOSell3,833$89.79$344,165.07View SEC Filing  
12/5/2013Paul MahonEVPSell6,000$89.18$535,080.00View SEC Filing  
12/5/2013Raymond DwekDirectorSell3,000$90.13$270,390.00View SEC Filing  
11/21/2013Martine RothblattCEOSell3,833$92.49$354,514.17View SEC Filing  
11/21/2013Paul MahonEVPSell6,000$92.47$554,820.00View SEC Filing  
11/15/2013Roger JeffsCOOSell10,000$94.00$940,000.00View SEC Filing  
11/14/2013Christopher PatuskyDirectorSell5,500$91.65$504,075.00View SEC Filing  
11/14/2013Martine RothblattCEOSell3,833$91.60$351,102.80View SEC Filing  
11/7/2013Christopher PatuskyDirectorSell3,500$90.51$316,785.00View SEC Filing  
11/7/2013Martine RothblattCEOSell3,833$89.47$342,938.51View SEC Filing  
11/7/2013Paul MahonEVPSell6,000$89.60$537,600.00View SEC Filing  
11/1/2013Raymond DwekDirectorSell3,000$89.18$267,540.00View SEC Filing  
11/1/2013Roger JeffsCOOSell10,000$90.34$903,400.00View SEC Filing  
10/31/2013Martine A RothblattCEOSell3,833$86.89$333,049.37View SEC Filing  
10/24/2013Martine A RothblattCEOSell3,833$83.77$321,090.41View SEC Filing  
10/18/2013Roger JeffsCOOSell10,000$82.47$824,700.00View SEC Filing  
10/17/2013John Maxim FerrariCFOSell2,750$82.01$225,527.50View SEC Filing  
10/17/2013Martine A RothblattCEOSell3,833$81.84$313,692.72View SEC Filing  
10/17/2013Paul A MahonEVPSell6,000$81.79$490,740.00View SEC Filing  
10/10/2013Martine RothblattCEOSell3,833$82.58$316,529.14View SEC Filing  
10/4/2013Roger JeffsCOOSell10,000$85.48$854,800.00View SEC Filing  
10/3/2013Christopher CauseyDirectorSell1,500$83.15$124,725.00View SEC Filing  
10/3/2013John Maxim FerrariCFOSell4,500$84.67$381,015.00View SEC Filing  
10/3/2013Martine A RothblattCEOSell3,833$84.20$322,738.60View SEC Filing  
10/3/2013Paul A MahonEVPSell6,000$84.38$506,280.00View SEC Filing  
9/26/2013Martine RothblattCEOSell3,833$78.41$300,545.53View SEC Filing  
9/20/2013Roger JeffsCOOSell10,000$77.86$778,600.00View SEC Filing  
9/19/2013John Maxim FerrariCFOSell4,500$78.67$354,015.00View SEC Filing  
9/19/2013Martine RothblattCEOSell3,833$78.12$299,433.96View SEC Filing  
9/19/2013Paul MahonEVPSell6,000$78.02$468,120.00View SEC Filing  
9/12/2013Martine A RothblattCEOSell3,833$76.98$295,064.34View SEC Filing  
9/6/2013Roger JeffsCOOSell10,000$73.67$736,700.00View SEC Filing  
9/5/2013Christopher CauseyDirectorSell1,500$73.11$109,665.00View SEC Filing  
9/5/2013John Maxim FerrariCFOSell4,500$74.17$333,765.00View SEC Filing  
9/5/2013Martine A RothblattCEOSell3,833$73.63$282,223.79View SEC Filing  
9/5/2013Paul A MahonEVPSell6,000$73.29$439,740.00View SEC Filing  
8/29/2013Martine RothblattCEOSell3,833$72.76$278,889.08View SEC Filing  
8/22/2013Martine RothblattCEOSell3,833$72.06$276,205.98View SEC Filing  
8/16/2013Roger JeffsCOOSell10,000$71.21$712,100.00View SEC Filing  
8/15/2013John Maxim FerrariCFOSell4,500$71.14$320,130.00View SEC Filing  
8/15/2013Martine RothblattCEOSell3,833$71.58$274,366.14View SEC Filing  
8/15/2013Paul MahonEVPSell6,000$71.34$428,040.00View SEC Filing  
8/8/2013Martine RothblattCEOSell3,833$73.11$280,230.63View SEC Filing  
8/2/2013Roger JeffsCOOSell10,000$76.69$766,900.00View SEC Filing  
8/1/2013John Maxim FerrariCFOSell4,500$75.87$341,415.00View SEC Filing  
8/1/2013Martine A RothblattCEOSell3,833$75.97$291,193.01View SEC Filing  
8/1/2013Paul A MahonEVPSell6,000$75.91$455,460.00View SEC Filing  
8/1/2013Raymond DwekDirectorSell3,000$75.94$227,820.00View SEC Filing  
7/31/2013R Paul GrayDirectorSell7,500$74.93$561,975.00View SEC Filing  
7/25/2013Martine A RothblattCEOSell3,833$71.45$273,867.85View SEC Filing  
7/19/2013Roger JeffsCOOSell10,000$70.00$700,000.00View SEC Filing  
7/18/2013John Maxim FerrariCFOSell9,000$69.85$628,650.00View SEC Filing  
7/18/2013Martine A RothblattCEOSell3,833$68.96$264,323.68View SEC Filing  
7/18/2013Paul A MahonEVPSell6,000$69.15$414,900.00View SEC Filing  
7/11/2013Martine A RothblattCEOSell3,837$67.94$260,685.78View SEC Filing  
7/5/2013Christopher CauseyDirectorSell1,500$66.33$99,495.00View SEC Filing  
7/5/2013Martine A RothblattCEOSell3,863$67.28$259,902.64View SEC Filing  
7/5/2013Paul A MahonEVPSell6,000$67.04$402,240.00View SEC Filing  
7/5/2013Roger JeffsCOOSell10,000$67.21$672,100.00View SEC Filing  
6/21/2013Roger JeffsCOOSell10,000$63.34$633,400.00View SEC Filing  
6/20/2013John Maxim FerrariCFOSell4,500$63.22$284,490.00View SEC Filing  
6/20/2013Paul A MahonEVPSell6,000$63.29$379,740.00View SEC Filing  
6/7/2013Roger JeffsCOOSell10,000$67.00$670,000.00View SEC Filing  
6/6/2013John Maxim FerrariCFOSell4,500$64.84$291,780.00View SEC Filing  
6/6/2013Paul A MahonEVPSell6,000$63.84$383,040.00View SEC Filing  
6/6/2013Raymond DwekDirectorSell3,000$63.77$191,310.00View SEC Filing  
5/17/2013Roger JeffsCOOSell10,000$69.17$691,700.00View SEC Filing  
5/16/2013John Maxim FerrariCFOSell4,500$68.48$308,160.00View SEC Filing  
5/16/2013Paul A MahonEVPSell6,000$68.05$408,300.00View SEC Filing  
5/2/2013Paul A MahonEVPSell6,000$67.15$402,900.00View SEC Filing  
5/2/2013Raymond DwekDirectorSell3,000$66.75$200,250.00View SEC Filing  
4/11/2013Raymond DwekDirectorSell9,000$61.35$552,150.00View SEC Filing  
1/17/2013Paul A MahonEVPSell5,749$52.20$300,097.80View SEC Filing  
12/28/2012Martine A RothblattCEOBuy4,167$52.40$218,350.80View SEC Filing  
12/26/2012Martine A RothblattCEOBuy6,000$52.40$314,400.00View SEC Filing  
12/21/2012Martine A RothblattCEOBuy9,000$51.85$466,650.00View SEC Filing  
11/26/2012Christopher CauseyDirectorSell1,500$53.33$79,995.00View SEC Filing  
10/4/2012Christopher CauseyDirectorSell1,500$58.33$87,495.00View SEC Filing  
10/4/2012John Maxim FerrariCFOSell1,550$58.00$89,900.00View SEC Filing  
10/4/2012Paul A MahonEVPSell6,000$38.00$228,000.00View SEC Filing  
9/6/2012Christopher CauseyDirectorSell1,500$55.94$83,910.00View SEC Filing  
9/5/2012Christopher PatuskyDirectorSell2,000$55.47$110,940.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for United Therapeutics Corporation (NASDAQ:UTHR)
Latest Headlines for United Therapeutics Corporation (NASDAQ:UTHR)
Source:
DateHeadline
americanbankingnews.com logoMartine A. Rothblatt Sells 1,274 Shares of United Therapeutics Corporation (UTHR) Stock
www.americanbankingnews.com - September 22 at 10:27 AM
finance.yahoo.com logoMartine Rothblatt is Featured in Forbes Magazine's Special Centennial Issue as one of The World's 100 Greatest Living Business Minds
finance.yahoo.com - September 19 at 9:09 AM
finance.yahoo.com logoMartine Rothblatt is Featured in Forbes Magazine's Special Centennial Issue as one of The World's 100 Greatest Living Business Minds
finance.yahoo.com - September 19 at 9:09 AM
americanbankingnews.com logoUnited Therapeutics Corporation (UTHR) Given Average Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - September 16 at 8:40 PM
americanbankingnews.com logoUnited Therapeutics Corporation (UTHR) CEO Martine A. Rothblatt Sells 1,258 Shares
www.americanbankingnews.com - September 15 at 8:03 PM
finance.yahoo.com logoUnited Therapeutics Corp. breached its 50 day moving average in a Bearish Manner : UTHR-US : September 11, 2017
finance.yahoo.com - September 12 at 11:42 AM
americanbankingnews.com logoUnited Therapeutics Corporation (UTHR) Earns Buy Rating from Oppenheimer Holdings, Inc.
www.americanbankingnews.com - September 11 at 3:12 PM
americanbankingnews.com logoUnited Therapeutics Corporation (UTHR) Expected to Announce Quarterly Sales of $430.87 Million
www.americanbankingnews.com - September 10 at 4:52 PM
americanbankingnews.com logoUnited Therapeutics Corporation (UTHR) Downgraded by ValuEngine
www.americanbankingnews.com - September 9 at 9:48 AM
finance.yahoo.com logoHere's Why United Therapeutics Sank as Much as 10.8% Today
finance.yahoo.com - September 9 at 9:35 AM
americanbankingnews.com logoMartine A. Rothblatt Sells 1,232 Shares of United Therapeutics Corporation (UTHR) Stock
www.americanbankingnews.com - September 8 at 8:20 PM
nasdaq.com logoFirst Week of UTHR October 20th Options Trading
www.nasdaq.com - September 8 at 9:55 AM
streetinsider.com logoUnited Therapeutics (UTHR) Reports FREEDOM-EV Study Of Orenitram To Continue As Planned Following Interim Analysis
www.streetinsider.com - September 8 at 9:55 AM
finance.yahoo.com logoUnited Therapeutics Announces FREEDOM-EV Study Of Orenitram® To Continue As Planned Following Interim Analysis
finance.yahoo.com - September 8 at 9:55 AM
americanbankingnews.com logoChristopher Causey Sells 580 Shares of United Therapeutics Corporation (UTHR) Stock
www.americanbankingnews.com - September 7 at 8:08 PM
nasdaq.com logoFirst Week of UTHR February 2018 Options Trading - Nasdaq
www.nasdaq.com - September 7 at 10:41 AM
americanbankingnews.com logoMartine A. Rothblatt Sells 1,235 Shares of United Therapeutics Corporation (UTHR) Stock
www.americanbankingnews.com - September 1 at 8:04 PM
finance.yahoo.com logoHow United Therapeutics’ Remodulin and Tyvaso Are Performing
finance.yahoo.com - September 1 at 10:31 AM
finance.yahoo.com logoLigand Pharmaceuticals Focuses on Increasing Returns for Shareholders
finance.yahoo.com - September 1 at 10:31 AM
finance.yahoo.com logoHow United Therapeutics’ Adcirca and Tyvaso Are Positioned in 3Q17
finance.yahoo.com - September 1 at 10:31 AM
finance.yahoo.com logoUnited Therapeutics Corp. breached its 50 day moving average in a Bullish Manner : UTHR-US : September 1, 2017
finance.yahoo.com - September 1 at 10:31 AM
americanbankingnews.com logoPrima BioMed (PBMD) versus United Therapeutics Corporation (UTHR) Head-To-Head Review
www.americanbankingnews.com - August 29 at 4:22 PM
finance.yahoo.com logoUnited Therapeutics Corp. – Value Analysis (NASDAQ:UTHR) : August 29, 2017
finance.yahoo.com - August 29 at 9:21 AM
americanbankingnews.com logoUnited Therapeutics Corporation (UTHR) CEO Martine A. Rothblatt Sells 1,238 Shares
www.americanbankingnews.com - August 25 at 8:32 PM
americanbankingnews.com logoComparing Repros Therapeutics (RPRX) & United Therapeutics (UTHR)
www.americanbankingnews.com - August 23 at 4:40 PM
americanbankingnews.com logoUnited Therapeutics Corporation (UTHR) Receives Average Rating of "Hold" from Analysts
www.americanbankingnews.com - August 22 at 8:44 PM
finance.yahoo.com logoUnited Therapeutics Corp. breached its 50 day moving average in a Bearish Manner : UTHR-US : August 21, 2017
finance.yahoo.com - August 22 at 7:35 AM
americanbankingnews.com logoReviewing Ampliphi Biosciences Corp (APHB) and United Therapeutics Corporation (UTHR)
www.americanbankingnews.com - August 21 at 4:22 AM
americanbankingnews.com logo Analysts Expect United Therapeutics Corporation (UTHR) Will Post Earnings of $4.00 Per Share
www.americanbankingnews.com - August 20 at 12:28 PM
americanbankingnews.com logoInsider Selling: United Therapeutics Corporation (UTHR) CEO Sells 1,235 Shares of Stock
www.americanbankingnews.com - August 17 at 8:32 PM
finance.yahoo.com logoUnited Therapeutics, Mayo Clinic to build lung restoration facility in Florida
finance.yahoo.com - August 15 at 7:56 AM
finance.yahoo.com logoETFs with exposure to United Therapeutics Corp. : August 11, 2017
finance.yahoo.com - August 11 at 8:43 PM
americanbankingnews.com logoMartine A. Rothblatt Sells 2,176 Shares of United Therapeutics Corporation (NASDAQ:UTHR) Stock
www.americanbankingnews.com - August 11 at 10:45 AM
finance.yahoo.com logoUnited Therapeutics Corp. breached its 50 day moving average in a Bearish Manner : UTHR-US : August 10, 2017
finance.yahoo.com - August 10 at 3:28 PM
finance.yahoo.com logoStealthy Viruses Take Center Stage In Efforts To Transplant Pig Organs Into People
finance.yahoo.com - August 10 at 3:28 PM
finance.yahoo.com logoSee what the IHS Markit Score report has to say about United Therapeutics Corp.
finance.yahoo.com - August 10 at 9:16 AM
bizjournals.com logoUnited Therapeutics sues FDA, HHS to get orphan drug designation ... - Washington Business Journal
www.bizjournals.com - August 9 at 8:52 AM
finance.yahoo.com logoUnited Therapeutics Corporation To Present At 2017 Wedbush PacGrow Healthcare Conference
finance.yahoo.com - August 9 at 8:51 AM
americanbankingnews.com logoFY2017 Earnings Forecast for United Therapeutics Corporation Issued By Wedbush (UTHR)
www.americanbankingnews.com - August 9 at 8:40 AM
seekingalpha.com logoUnited Therapeutics: The Expectations Are Too Low. - Seeking Alpha
seekingalpha.com - August 8 at 7:59 AM
americanbankingnews.com logoUnited Therapeutics Corporation to Post Q3 2017 Earnings of $3.79 Per Share, Wedbush Forecasts (NASDAQ:UTHR)
www.americanbankingnews.com - August 8 at 7:08 AM
benzinga.com logoWall Street's M&A Chatter From August 4-7: Acadia Pharma, United Technologies-Rockwell Collins, United Therapeutics - Benzinga
www.benzinga.com - August 7 at 8:01 AM
nasdaq.com logoUnited Therapeutics Breaks Above 200-Day Moving Average - Bullish for UTHR
www.nasdaq.com - August 5 at 8:15 AM
americanbankingnews.com logoUnited Therapeutics Corporation (NASDAQ:UTHR) CEO Martine A. Rothblatt Sells 1,248 Shares
www.americanbankingnews.com - August 4 at 8:40 PM
investorplace.com logoUnited Therapeutics Corporation (UTHR) Shares Soar on Takeover Talk
investorplace.com - August 4 at 5:37 PM
nasdaq.com logoPre-Market Most Active for Aug 4, 2017 : ETP, BA, HCLP, OKE, BAC, GPRO, SUN, QQQ, USLV, TLT, UTHR, AAOI - Nasdaq
www.nasdaq.com - August 4 at 9:38 AM
businesswire.com logoRobbins Arroyo LLP Is Investigating the Officers and Directors of United Therapeutix Corporation (UTHR) on Behalf of ... - Business Wire (press release)
www.businesswire.com - August 4 at 9:38 AM
marketwatch.com logoUnited Therapeutics Corp. stock surges 9% on report of possible bids for company - MarketWatch
www.marketwatch.com - August 4 at 9:38 AM
finance.yahoo.com logoRobbins Arroyo LLP Is Investigating the Officers and Directors of United Therapeutix Corporation (UTHR) on Behalf of Shareholders
finance.yahoo.com - August 4 at 9:38 AM
finance.yahoo.com logoMorning Movers: Viacom Tumbles on Earnings; United Therapeutics Soars
finance.yahoo.com - August 4 at 9:38 AM

Social

Chart

United Therapeutics Corporation (UTHR) Chart for Saturday, September, 23, 2017

This page was last updated on 9/23/2017 by MarketBeat.com Staff